Scaffolds fabricated from electrospun decellularized extracellular matrix
US-2019142998-A1 · May 16, 2019 · US
US12186454B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12186454-B2 |
| Application number | US-202318100000-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 23, 2023 |
| Priority date | Apr 12, 2016 |
| Publication date | Jan 7, 2025 |
| Grant date | Jan 7, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A scaffold comprising electrospun decellularized ECM of an organ, wherein the decellularized ECM has a similar protein composition to native ECM of the organ. Methods of generating same are also disclosed as well as uses of same.
Opening claim text (preview).
What is claimed is: 1. A method of generating a scaffold comprising: (a) homogenizing decellularized extracellular matrix (ECM) in an organic solvent using a bead homogenizer to generate a homogenate of decellularized ECM; (b) contacting said homogenate of decellularized ECM with a synthetic polymer so as to increase viscoelasticity of said homogenate of decellularized ECM, wherein an amount of said synthetic polymer in said homogenate of decellularized ECM is between 0.05-1% mass of said homogenate of decellularized ECM; and subsequently (c) electrospinning said homogenate of decellularized ECM onto a solid surface thereby generating the scaffold composed of ECM fibers; and subsequently (d) removing said polymer following said electrospinning such that the scaffold is devoid of said synthetic polymer, wherein the method is performed in-vitro. 2. The method of claim 1 , wherein said ECM is not derived from fat tissue. 3. The method of claim 1 , wherein said ECM is derived from an organ selected from the group consisting of heart and pancreas. 4. The method of claim 1 , further comprising decellularizing a tissue of a subject to generate said decellularized ECM prior to step (a). 5. The method of claim 1 , wherein said homogenizing is effected at 6000 rpm. 6. The method of claim 1 , wherein said organic solvent is selected from the group consisting of acetone, N,N-dimethylformamide (DMF), diethylformamide, chloroform, methylethylketone, acetic acid, formic acid, ethanol, 1,1,1,3,3,3-hexa fluoro-2-propanol (HFIP), tetrafluoroethanol, dichloromethane (DCM), tetrahydrofuran (THF), trifluoroacetic acid (TFA), camphorsulfonic acid, dimethyl acetamide, isopropyl alcohol (IPA) and mixtures thereof. 7. The method of claim 1 , wherein said organic solvent is HFIP. 8. The method of claim 1 , wherein said synthetic polymer is selected from the group consisting of poly(D,L-lactide) (PLA), poly(urethanes), poly(siloxanes), poly(silicones), poly(ethylene), poly(vinyl pyrrolidone), poly(2-hydroxy ethyl methacrylate), poly(N-vinyl pyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol) (PVA), poly(acrylic acid), poly(vinyl acetate), polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene glycol), poly(methacrylic acid), polyglycolic acids (PGA), poly(lactide-co-glycolides) (PLGA), nylons, polyamides, polyanhydrides, poly(ethylene-co-vinyl alcohol) (EVOH), polycaprolactone, poly(vinyl acetate), polyvinylhydroxide, poly(ethylene oxide) (PEO), polyorthoesters and mixtures thereof. 9. The method of claim 8 , wherein said synthetic polymer is PEO. 10. The method of claim 1 , further comprising sonicating said homogenate of decellularized ECM following step (a) and prior to step (b). 11. The method of claim 1 , further comprising mixing said homogenate of decellularized ECM by placing on a rotator for at least 1 day prior to step (b). 12. The method of claim 1 , further comprising filtering said homogenate of decellularized ECM to remove any particulate matter following step (a) and prior to step (c). 13. The method of claim 1 , wherein said removing is by rinsing in an aqueous solution.
Collagen · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Drugs for disorders of the cardiovascular system · CPC title
containing added animal cells (organs or tissue containing native cells A61L27/36) · CPC title
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.